Drug Pipeline Database & Screener


Over 2000 drug entries from about 500 biotech companies in Phase 2, 3 or NDA development.

Company SCREENER also available to filter through financial and clinical data. Financial filters include market cap, short ratio, price to book and relative volume, while you can also run a filter according to the development stage of the drug (e.g. Phase 2, PDUFA date).

"Phases" refer to the stage of drug development. The development process of a drug is as follows:

1) Preclinical trials - Animal testing to test safety.

2) Clinical trials - Testing on humans to test safety and efficacy. Generally there are three trials (Phase 1-3). Drugs to feature on BioPharmCatalyst are mainly in Phase 2 or 3 development. Phase 1 drugs are generally not included unless they are attached to a company with a small pipeline or considered blockbuster status. Over time, this list will grow.

3) FDA Review - If a drug successfully completes the clinical trial process the FDA will review the drug and decide whether to approve or not approve it. The FDA assigns a PDUFA goal date by which it will make its final decision.

N.B. The short ratio is the number of shares sold short divided by the average daily volume, also known as the number of "days to cover".

NASDAQ and NYSE stocks only are shown. OTC stocks are not covered on BioPharmCatalyst.

Refer to the Biotech Historical Catalyst Calendar for completed biotech stock catalysts.

Visit the FDA Calendar for  latest Biotech Stock Catalyst dates (PDUFA dates and clinical data readouts).

Alternatively, the BioPharmCatalyst Biotech Stocks page provides data on daily price and volume movers and information on individual companies.

Drug pipeline data are updated at the end of each trading day. Click on the date for the source of the catalyst. 

Subscribe HERE to ensure you receive your weekly free copy of the BioPharmCatalyst Biotech Watchlist and/or our daily option of Biotech Price Movers and Pipeline Database updates. 

Financial data are delayed 15-25 minutes.

Showing 511 companies
Screener
Sort
Stage
Indication
Market Cap
Price
Short ratio
Relative Volume
Price to book
FDA Calendar
Company
Price
Change
No of Shares
Market Cap
Short Ratio
Updated
$88.91
-1.04  -1.16%
1.6 billion
$141.1 billion
4.05
07/20/2018
Tap to view 36 drugs
Drug Indication Stage News
ABT-494 - SELECT-MONOTHERAPY Rheumatoid arthritis Phase 3 Phase 3 data released December 20, 2017 - primary endpoint and key secondary endpoints met.
Risankizumab Ulcerative colitis Phase 3 Phase 3 trial to be initiated 1H 2018.
ABT-494 - SELECT-COMPARE Rheumatoid arthritis Phase 3 Phase 3 data released April 9, 2018. Primary and secondary endpoints met.
ABT-414 Recurrent glioblastoma (rGBM) Phase 1 Phase 1 data at ASCO. Oral Abstract 2003. June 4, 2017.
ABT-494 - SELECT-BEYOND Rheumatoid arthritis Phase 3 Phase 3 top-line released September 11, 2017. Endpoints met but with two patient deaths.
Veliparib Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC) Phase 3 Phase 3 trial did not meet primary endpoints - April 19, 2017.
Ibrutinib Relapsed or refractory MCL mantle cell lymphoma Approved Approved November 13, 2013.
Imbruvica Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy Approved Approved February 12, 2014.
Imbruvica Deletion 17p Approved Approved July 19, 2014.
VIEKIRA PAK HCV - genotype 1 Approved Approved December 19, 2014.
IMBRUVICA Waldenström’s Macroglobulinemia Approved Approved January 29, 2015 - PCYC
ABBV-8E12 Progressive supranuclear palsy (PSP) Phase 2 Phase 2 initiation announced January 25, 2017.
ABBV-8E12 Alzheimer's disease Phase 2 Phase 2 initiation announced January 25, 2017.
Venclexta (MURANO) Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) Approved Approval announced June 11, 2018.
Venetoclax Relapsed or refractory multiple myeloma Phase 3 Phase 3 trial initiated July 2016.
Venclexta First-line Diffuse large B-cell lymphoma (DLBCL) Phase 3 Phase 3 trial planned.
Venclexta Follicular lymphoma (FL) Phase 3 Phase 3 trial planned.
Risankizumab Crohn’s Disease Phase 3 Phase 3 trial to commence 2H 2017.
Risankizumab Psoriasis BLA Filing Phase 3 data released October 26, 2017 - primary endpoints met. BLA filing announced April 25, 2018.
Imbruvica Second-line Chronic graft-versus-host disease (GVHD) Approved Approval announced August 2, 2017.
ABT-494 Psoriatic Arthritis Phase 3 Phase 3 trial to commenced 2017.
ABT-494 (upadacitinib) - SELECT-NEXT Rheumatoid arthritis Phase 3 Phase 3 top-line data released June 7, 2017 - primary endpoints met.
Risankizumab Psoriatic Arthritis Phase 2b Phase 3 trial planned for 2018.
ABT-494 Crohn’s Disease Phase 3 Phase 3 trial initiated late 2017.
Rova-T (TRINITY) Third-line Small Cell Lung Cancer Phase 2 Phase 2 pivotal data released March 22, 2018. ORR of 16% + overall survival 5.6 months noted. Abstract 8507.
ABT-494 Atopic Dermatitis Phase 3 Phase 2b data released September 7, 2017 - primary endpoint met. Phase 3 trial to be initiated 1H 2018.
Imbruvica Marginal zone lymphoma Approved sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Glecaprevir/Pibrentasvir (G/P) Hepatitis C virus (HCV) Approved Approval announced August 3, 2017.
Elagolix Uterine Fibroids Phase 3 Phase 3 data released February 21, 2018 - primary endpoint met. Second Phase 3 trial also met primary endpoint - March 13, 2018.
Elagolix Endometriosis PDUFA priority review Phase 3 trials met both co-primary endpoints - Jan 2015. Priority review announced October 27, 2017. Announced April 10, 2018 that PDUFA date has been extended by three months. New date likely late July/early August 2018. Exact PDUFA date not announced.
ABT-494 - SELECT-EARLY Rheumatoid arthritis Phase 3 Phase 3 trial met all endpoints - June 5, 2018. Regulatory filing due 2H 2018.
Rova-T (TAHOE) Second-line Small Cell Lung Cancer Phase 3 Phase 3 data due 2020.
Rova-T (MERU) First-line Small Cell Lung Cancer Phase 3 Phase 3 data due 2020.
Imbruvica and Gazyva - iLLUMINATE Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) Phase 3 Phase 3 trial met PFS primary endpoint - May 24, 2018.
IMBRUVICA (ibrutinib) Waldenström’s Macroglobulinemia PDUFA priority review sNDA accepted June 25, 2018. PDUFA date under priority review granted.
IMBRUVICA (ibrutinib) Diffuse large B-cell lymphoma (DLBCL) Phase 3 Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
$14.35
+0.15  +1.06%
47.3 million
$678.8 million
12.83
07/20/2018
Tap to view 4 drugs
Drug Indication Stage News
ABO-101 Sanfilippo syndrome type B (MPS IIIB) Phase 1/2 Phase 1/2 commencement of enrollment announced December 20, 2017.
EB-101 Recessive dystrophic epidermolysis bullosa (RDEB) Phase 1/2 Phase 1/2 poster due at Society for Investigative Dermatology (SID) April 28, 2017. Noted January 29, 2018 intention to commence Phase 3 trial in 2018.
ABO-101 Recessive dystrophic epidermolysis bullosa (RDEB) Phase 2 Phase 2 enrollment commenced September 2016.
ABO-102 Sanfilippo syndrome type A (MPS IIIA) Phase 1/2 Phase 1/2 updated data released February 8, 2018. CSF heparan sulfate levels decreased 57%/64%.
$0.59
+0.02  +2.81%
13.9 million
$8.2 million
0.42
07/20/2018
Tap to view 1 drug
ABLX Ablynx NV
$0.00
  +0.00%
78 million
$
0.09
07/20/2018
Tap to view 5 drugs
Drug Indication Stage News
ALX-0171 Respiratory syncytial virus (RSV) Phase 2 Phase 2 trial initiation announced April 29, 2018. Data due 2H 2018.
Caplacizumab Acquired thrombotic thrombocytopenic purpura (aTTP) Phase 3 BLA filing due 1H 2018.
Vobarilizumab Rheumatoid Arthritis Phase 2b Phase 2b completed. Awating opt-in decision from Abbvie expected 2018.
Vobarilizumab Systemic lupus erythematosus (SLE) Phase 2 Phase 2 trial did not meet primary endpoint - March 26, 2018.
ALX-0171 Infants Hospitalized for Respiratory Syncytial Virus Phase 2b Phase 2b data due 2H 2018.
$11.55
+0.15  +1.32%
55.2 million
$637.2 million
6.5
07/20/2018
Tap to view 6 drugs
Drug Indication Stage News
ARB-1467, tenofovir, and pegylated interferon Hepatitis B (HBV) Phase 2 Phase 2 interim data due 4Q 2018.
AB-423 (MAD) Hepatitis B (HBV) Phase 2 Phase 2 trial to be initiated 1Q 2018.
ARB-1467 Hepatitis B (HBV) Phase 2 Phase 2 Cohort 4 data released September 25, 2017 with detailed data due at AASLD in October 2017.
Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR PDUFA priority review PDUFA date under priority review August 11, 2018. ABUS entitled to low-mid single digit royalties.
AB-452 Hepatitis B Phase 1 Phase 1 trial to be initiated 4Q 2018 with trial completion slated for 3Q 2019.
AB-506 Hepatitis B (HBV) Phase 1 Phase 1 data due 2Q 2019.
$16.84
-0.24  -1.41%
124.8 million
$2.1 billion
5.18
07/20/2018
Tap to view 6 drugs
Drug Indication Stage News
Pimavanserin - CLARITY Adjunctive Treatment in Patients With Major Depressive Disorder Phase 2 Phase 2 initiation announced December 1, 2016. Top-line data due 2H 2018.
Pimavanserin - Advance Adjunctive treatment in patients with negative symptoms of schizophrenia Phase 2 Phase 2 initiated November 2016. Data due 2019.
Pimavanserin - Enhance Adjunctive treatment of schizophrenia Phase 3 Phase 3 initiated November 2016. Data due 2019.
Pimavanserin - SERENE Alzheimer’s disease agitation Phase 2 Announced October 4, 2017 that trial will be discontinued.
Pimavanserin Parkinson’s disease psychosis (PDP) Approved Approved April 29 2016. Additional dose approval announced June 29, 2018.
Pimavanserin - Harmony Alzheimer’s disease psychosis Phase 3 Phase 3 trial initiation announced October 4, 2017.
$20.25
-0.1  -0.49%
7.5 million
$151.8 million
0.54
07/20/2018
Tap to view 3 drugs
Drug Indication Stage News
EDSIVO Vascular Ehlers-Danlos Syndrome Phase 3 NDA filing planned for 2Q 2018.
Tovaxin (Tcelna) Secondary Progressive MS (SPMS) Phase 2b Phase 2b trial did not meet primary endpoint - October 28, 2016.
ACER-001 Urea cycle disorder (UCD) Phase 2 NDA filing planned for 2019.
$2.86
-0.12  -4.03%
138.3 million
$395.7 million
4.91
07/20/2018
Tap to view 7 drugs
Drug Indication Stage News
ACH-4471 C3 glomerulopathy (C3G) Phase 2 Phase 2 interim data due 3Q 2018.
JNJ-4178 Hepatitis C (HCV) Phase 2a Janssen noted September 11, 2017 that no further development planned.
ACH-4471 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 2 Phase 2 initiation announced April 6, 2017. Interim data released August 8, 2017 with further data due 4Q 2018.
JNJ-4178 - OMEGA-1 Hepatitis C (HCV) Phase 2b Janssen noted September 11, 2017 that no further development planned.
ACH-4471 C3 glomerulopathy (C3G) Phase 2 Phase 2 longer duration data due 2H 2018.
ACH-5228 Healthy volunteers Phase 1 Phase 1 data due 4Q 2018.
ACH-5548 Healthy volunteers Phase 1 Phase 1 trial initiation announced July 10, 2018. Interim data due 2H 2018.
$3.30
-0.05  -1.49%
2.8 million
$9.1 million
0.11
07/20/2018
Tap to view 1 drug
Drug Indication Stage News
Cytisine Smoking cessation Phase 2b Phase 2b trial to be initiated 4Q 2018 with data due 3Q 2019.
$16.28
+1.97  +13.77%
57.4 million
$934.5 million
62.36
07/20/2018
Tap to view 6 drugs
Drug Indication Stage News
Crenezumab - CREAD 2 Alzheimer’s disease Phase 3 Second Phase 3 trial initiation announced February 28, 2017. Noted July 16, 2018 that trial is fully recruited. Data due 2021.
RO7105705 Alzheimer’s disease Phase 1b Phase 2 commencement of dosing announced November 2, 2017.
ACI-24 (anti-Abeta vaccine) Alzheimer's disease-like characteristics in individuals with Down syndrome Phase 1/2 Phase 1/2 completion of recruitment of low-dose cohort noted September 12, 2017. Interim data due 2018.
Crenezumab - CREAD 1 Alzheimer’s disease Phase 3 Phase 3 trial commennced 1Q 2016. Phase 2 trial did not meet co-primary endpoints. IPO September 23, 2016. Data due 2020.
ACI-24 Alzheimer’s disease Phase 2 Phase 2 trial planned.
ACI-35 Alzheimer’s disease Phase 1b Phase 2 trial planned.
$20.48
+0.05  +0.24%
30.9 million
$633 million
17.97
07/20/2018
Tap to view 8 drugs
Drug Indication Stage News
ATI-502 (AA-201 Topical) - dose ranging Alopecia areata Phase 2 Phase 2 data due year-end 2018.
ATI-502 (VITI-201 Topical) Vitiligo Phase 2 Phase 2 open label trial initiation announced December 19, 2017 with data due 1H 2019.
ATI-502 AUATB-201 - open label Alopecia areata - regrowth of eyebrows Phase 2 Phase 2 data due mid-2018.
ATI-501 (AUAT-201 Oral) Alopecia areata Phase 2 Phase 2 trial to be initiated 1H 2018 with data due mid-2019.
ESKATA (hydrogen peroxide) Seborrheic keratosis (SK) Approved Approval announced December 15, 2017.
A-101 Common warts (verruca vulgaris) Phase 2 Phase 2 data released January 8, 2018 - endpoints met. Phase 3 trial to be initiated 2H 2018.
ATI-502 AA-202 Topical - PK/safety Alopecia areata Phase 2 Phase 2 interim data released June 28, 2018.
ATI-502 - open label Androgenetic alopecia (AGA) - Hair loss Phase 2 Phase 2 data due 1H 2019.
$2.95
  +0.00%
51.3 million
$151.4 million
4.63
07/20/2018
Tap to view 3 drugs
Drug Indication Stage News
ARX-04 (SAP302) Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury Phase 3 Phase 3 data released August 15 2016
DSUVIA (ARX-04) Moderate-to-severe acute pain following a surgical procedure PDUFA CRL issued October 12, 2017. NDA resubmission announced May 9, 2018 with new PDUFA date November 3, 2018.
Zalviso Post-operative pain following open abdominal surgery and hip or knee replacement surgery Phase 3 CRL Jul 26 2014. Additional clinical trial required. Data released August 1, 2017. NDA resubmission due 2H 2018.
$0.56
+0.01  +2.47%
36.2 million
$20.4 million
1.34
07/20/2018
Tap to view 1 drug
Drug Indication Stage News
CaPre (TRILOGY trial) Hypertriglyceridemia Phase 3 Phase 3 patients randomized - noted March 14, 2018 with top-line data due by the end of 2019.
$10.44
-0.54  -4.92%
94.1 million
$982.9 million
4.95
07/20/2018
Tap to view 8 drugs
Drug Indication Stage News
NY-ESO T-cell therapy Synovial sarcoma - cancer Phase 1/2 Oral presentation at CTOS November 9, 2017.
NY-ESO T-cell therapy Ovarian cancer Phase 1/2 Reported no clinical responses October 2016. Intends to alter dosage to include fludarabine.
NY-ESO T-cell therapy Myxoid round cell liposarcoma (MRCLS) Phase 1/2 Phase 1/2 data released ASCO June 2018 - 3 PRs, 1 unconfirmed PR, 3 SD out of 8 patients.
NY-ESO T-cell therapy Myeloma Phase 1/2 Updated data at ASH December 2017 - Overall response rate (ORR) at 100 days and one year were 76% and 44%.
NY-ESO T-cell therapy Non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1/2 initiated November 2015. Data are due 2017.
MAGE-A4 Soild tumors Phase 1 Phase 1 response data due 2H 2018.
AFP Hepatocellular carcinoma Phase 1 Initial safety data due late 2018.
MAGE-A10 Non-Small Cell Lung Cancer (NSCLC) Phase 1 Phase 1 response data due 2H 2018.
$4.84
+0.03  +0.62%
46.3 million
$224.3 million
3.82
07/20/2018
Tap to view 1 drug
$3.80
+0.15  +4.11%
33.4 million
$126.9 million
7.93
07/20/2018
Tap to view 3 drugs
Drug Indication Stage News
Epinephrine Pre-filled Syringe (PFS) Emergency treatment of anaphylaxis. Approved CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.
APC-1000 Asthma/COPD Phase 2 Phase 3 planned for 2018.
Symjepi - low dose Anaphylaxis PDUFA sNDA filing to included lower dose. PDUFA date September 3, 2018.
$27.09
-0.04  -0.15%
27 million
$731 million
14.07
07/20/2018
Tap to view 5 drugs
Drug Indication Stage News
ADS-4101 Partial onset seizures in patents with epilepsy Phase 1b Phase 1b top-line data released September 7, 2017. Pivotal Phase 3 trial to be initiated 2019.
GOCOVRI (amantadine) Multiple sclerosis (MS) Phase 3 Phase 3 commencement of enrollment announced April 3, 2018. Enrollment to be completed 2H 2019.
Namzaric Moderate to severe dementia of the Alzheimer's type. Approved Approved December, 24 2014.
ADS-5102 Levodopa-Induced Dyskinesia Approved Approval announced August 24, 2017.
GOCOVRI (amantadine) Dyskinesia patients with Parkinson's disease Phase 3 Phase 3 open-label data released April 19, 2018.
$6.90
-0.15  -2.13%
78.7 million
$543.2 million
11.52
07/20/2018
Tap to view 9 drugs
Drug Indication Stage News
BION-1301 Multiple Myeloma Phase 1/2 Phase 1/2 initiation announced December 18, 2017.
ADU-S100 Solid tumors or lymphomas Phase 1b Initial data due 2H 2018.
CRS-207 and GVAX Pancreas - ECLIPSE trial Pancreatic cancer Phase 2b Phase 2b primary endpoint not met - May 2016
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial Pancreatic cancer Phase 2b Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
CRS-207 with pembrolizumab Mesothelioma - cancer Phase 2 Noted December 12, 2017 that development to be discontinued.
ADU-S100 and PDR001 Solid tumors or lymphomas Phase 1b Initial data due 2H 2018.
pLADD Colorectal Cancer Phase 1 Phase 1 additional additional immunological data due by end of 2018.
pLADD Colorectal Cancer Phase 1 Phase 1 additional additional immunological data due by end of 2018.
ADU-214 with Nivolumab Non-Small Cell Lung Cancer Phase 1/2 Phase 1b initiation announced June 7, 2018.
$5.05
-0.1  -1.94%
62.3 million
$314.5 million
5.33
07/20/2018
Tap to view 2 drugs
$1.48
+0.03  +2.07%
52.6 million
$77.9 million
3.2
07/20/2018
Tap to view 8 drugs
Drug Indication Stage News
Axalimogene filolisbac + durvalumab Recurrent or refractory HPV-associated cervical cancer and head & neck cancer Phase 1/2 Clinical hold announced March 2018 released July 13, 2018.
ADXS-PSA and Keytruda - KEYNOTE-046 Castrate-resistant prostate cancer Phase 1/2 Part B monotherapy data due 1Q 2019.
Axalimogene filolisbac - AIM2CERV Trial High-risk, locally advanced cervical cancer Phase 3 Announced Phase 3 first patient dosed - February 6, 2017. Noted June 7, 2018 that unless partner is found soon trial will be terminated.
Axalimogene filolisbac - GOG 0265 study Cervical cancer Phase 2 Phase 2 top-line data released October 24, 2016. Second stage was not completed due to the clinical hold in 2015.
ADXS-HER2 HER2-driven malignancies - cancer Phase 1b Decided not to proceed to the expansion phase of the trial - noted in 10K December 21, 2017.
Axalimogene filolisbac Anal cancer (FAWCETT) Phase 2 Noted in 10-K December 21, 2017 that it will not initiate the Stage 2 portion of the trial in order to focus its resources on other clinical priorities.
ADXS-NEO Non-small cell lung cancer (NSCLC) Phase 1 Phase 1 initiation of dosing announced June 11, 2018. Data from initial cohort due 2019.
ADXS-503 Non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1/2 trial to be initiated by the end of 2018.
$73.40
-0.5  -0.68%
39.5 million
$2.9 billion
11.76
07/20/2018
Tap to view 2 drugs
Drug Indication Stage News
Roclatan - Mercury trials Glaucoma NDA Filing NDA filing announced May 15, 2018.
Rhopressa Glaucoma Approved PDUFA date February 28, 2018. Approved ahead of schedule - December 18, 2017.
$1.92
-0.02  -1.03%
16.4 million
$31.6 million
2.98
07/20/2018
Tap to view 2 drugs
Drug Indication Stage News
Macimorelin Acetate - Macrilen Adult Growth Deficiency Approved CRL issued November 2014. Approval announced following resubmission December 20, 2017.
Zoptrex Endometrial cancer Phase 3 Phase 3 trial did not meet primary endpoint - May 1, 2017.
$1.81
+0.04  +2.11%
62.4 million
$113.1 million
0.75
07/20/2018
Tap to view 3 drugs
Drug Indication Stage News
AFM13 with Keytruda Hodgkin Lymphoma - Cancer Phase 1b Phase 1b data presented at EHA June 2018. ORR of 89% (16/18 patients).
AFM13 Hodgkin Lymphoma - Cancer Phase 2 Phase 2a ongoing.
AFM13 CD30-positive lymphoma Phase 1/2 Phase 1b/2a preliminary data showed 1/3 PR. 1/3CR, 1/3 SD - released February 1, 2018.
$2.12
-0.12  -5.36%
104 million
$220.5 million
5.44
07/20/2018
Tap to view 7 drugs
Drug Indication Stage News
AGEN2034 and AGEN1884 Solid tumors Phase 1/2 Phase 1/2 enrollment has been completed - noted January 22, 2018.
AGEN1884 (anti-CTLA-4) Solid cancers Phase 1 Phase 1 presentation at ASCO 2018. 31% ORR.
Shingrix Shingles Approved Approval announced October 20, 2017.
AGEN2034 (anti-PD-1) Cervical cancer Phase 1/2 Phase 1/2 enrollment has been completed - noted January 22, 2018. Data due 4Q 2019.
INCAGN1949 Solid tumors - cancer Phase 1/2 Phase 1/2 trial initiation announced November 30, 2016.
INCAGN1876 Solid tumors - cancer Phase 1/2 Phase 1/2 trial commenced June 2016
AGEN 1884 plus Keytruda Non-small cell lung cancer (NSCLC) Phase 2 Phase 2 data due 2018.
$91.06
-0.12  -0.13%
57.6 million
$5.2 billion
12.51
07/20/2018
Tap to view 12 drugs
Drug Indication Stage News
AG-348 Thalassemia Phase 2 Phase 2 trial to be initiated 4Q 2018.
Ivosidenib IDH1m Relapsed/Refractory AML - cancer Approved FDA Approval announced July 20, 2018.
AG-348 Pyruvate kinase deficiency Phase 3 Phase 3 trial initiation announced June 18, 2018.
AG-120 and VIDAZA - AGILE Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer Phase 3 Phase 3 initiated 2Q 2017.
Enasidenib (AG-221) - IDHENTIFY Refractory Acute myeloid leukemia (AML) - cancer Phase 3 Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of January 2018.
IDHIFA (enasidenib) - AG-221 Advanced hematologic malignancies with an IDH2 mutation Approved Approval announced August 1, 2017.
AG-120 Ivosidenib IDH1 mutant positive cholangiocarcinoma - cancer Phase 3 Phase 3 initiated December 2016. Enrollment to be completed 1H 2019.
AG-120 Ivosidenib R/R Acute Myeloid Leukemia (AML) Phase 1 Phase 1 data at ASCO June 2018 noted CR rate was 24%.
Enasidenib or ivosidenib with VIDAZA Frontline AML with IDH1 or IDH2 mutation Phase 1/2 Phase 1/2 updated data at ASCO June 2018. ORR of 78%, CR Rate of 44%.
Ivosidenib or enasidenib Frontline AML with IDH1 or IDH2 mutation Phase 1 Phase 1 first data presented at ASH 2017 with updated data due at ASH 2018. Phase 3 trial to be initiated 4Q 2018.
AG-270 Solid tumors Phase 1 Phase 1 dosing of first patient announced March 19, 2018.
AG-881 Glioma Phase 1 Phase 1 data presented at ASCO June 1, 2018. 1 minor response + 1 partial response out of 93 patients.
$9.20
-0.11  -1.18%
21.9 million
$201.1 million
2.7
07/20/2018
Tap to view 7 drugs
Drug Indication Stage News
AEB1102 + KEYTRUDA Small cell lung cancer (SCLC) Phase 1/2 Phase 1/2 top-line safety and clinical data due 4Q 2018.
AEB1102 Acute myeloid leukemia (AML) or Myelodysplastic syndromes (MDS) Phase 1 Phase 1 initiation announced July 2016. Enrollment to be completed in 2017.
Pegzilarginase (AEB1102) Arginase I deficiency Phase 1/2 Phase 1/2 new data presented April 12, 2018. Top-line data due 3Q 2018.
AEB1102 Solid tumors Phase 1 Phase 1 dose escalation data presented at AACR April 15, 2018.
Pegzilarginase (AEB1102) Solid tumors Phase 1 Phase 1 data due 4Q 2018.
Pegzilarginase (AEB1102) + KEYTRUDA Small cell lung cancer (SCLC) Phase 1/2 Phase 1/2 top-line safety and clinical data due 4Q 2018.
AEB1102 Solid tumors Phase 1 Monotherapy data due 4Q 2018.
$171.79
-1.6  -0.92%
339.1 million
$58.2 billion
1.4
07/20/2018
Tap to view 25 drugs
Drug Indication Stage News
Botox Forehead lines Approved Approval (third indication) announced October 3, 2017.
ABP 980 Herceptin biosimilar BLA Filing BLA filing announced July 31, 2017.
RTGel in combination with BOTOX Overactive Bladder (OAB) Phase 2 Phase 2 trial initiation announced November 6, 2017.
JUVÉDERM VOLLURE Correction of moderate to severe facial wrinkles and folds Approved Approval announced March 20, 2017.
Brazikumab Crohn's disease Phase 2b Phase 3 to be initiated 2H 2018.
Bimatoprost Androgenic Alopecia Phase 3 Phase 3 enrollment to be completed 2H 2018.
Botox Depression Phase 2 Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned.
Cariprazine Bipolar I depression Phase 3 Phase 3 data released December 18, 2017 - primary endpoint met.
RORγt agonist Psoriasis Phase 2b Phase 2b trial ongoing.
Cariprazine Maintenance Treatment of Schizophrenia Approved Approval announced November 13, 2017.
ATOGEPANT Prophylaxis (migraine) Phase 2b Phase 2b top-line data released June 11, 2018 - primary endpoint met.
UBROGEPANT Acute (migraine) Phase 3 Phase 3 data released February 6, 2018 - primary endpoints met.
RAPASTINEL Major depressive disorder (MDD) Phase 3 Phase 3 initiated October 2016. Data due 2H 2019.
RELAMORELIN Diabetic Gastroparesis Phase 3 Phase 3 initiated 2H 2017 with top-line data due 2020.
ESMYA (ulipristal acetate) Uterine Fibroids PDUFA Phase 3 data released January 18, 2017 - endpoints met. Noted February 28, 2018 that PDUFA date has been extended to August 2018.
ABICIPAR Diabetic macular edema (DME) Phase 3 Phase 3 trial to be initiated 2H 2018.
Cenicriviroc (CVC) Nonalcoholic steatohepatitis (NASH) Phase 3 Phase 3 trial has been initiated.
ABICIPAR Age-related macular degeneration (AMD) Phase 3 Phase 3 data released July 19, 2018. Primary endpoint met.
AVYCAZ (ceftazidime and avibactam) Complicated Urinary Tract Infections (cUTI) Approved sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017.
Oxymetazoline HCl cream 1.0% Facial Erythema (Redness) Associated with Rosacea Approved Approved January 19, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults Chronic idiopathic constipation (CIC) Approved sNDA approval announced January 26, 2017.
MVASITM (bevacizumab-awwb) Biosimilar candidate to Avastin (bevacizumab) Approved Approved September 14, 2017.
Sarecycline Severe acne vulgaris PDUFA PDUFA date 4Q 2018. Exact date not provided by company. Estimate October 19, 2018 based on NDA acceptance date of December 20, 2017.
Cariprazine Bipolar I Depression Phase 3 Phase 3 data released April 3, 2018. Primary endpoint met. sNDA filing due 2H 2018.
UBROGEPANT - ACHIEVE II (UBR-MD-02) Migraine Phase 3 Phase 3 data due released April 27, 2018. High dose met both primary endpoints. Low dose met one of two.
$0.49
-0.02  -4.88%
34.2 million
$16.6 million
0.38
07/20/2018
Tap to view 1 drug
$4.05
-0.1  -2.41%
18.1 million
$73.3 million
2.61
07/20/2018
Tap to view 3 drugs
Drug Indication Stage News
AAV Gene Therapy CNGB3 Achromatopsia Phase 1/2 Phase 1/2 continues to enroll - September 2017.
rAAV-hRS1 X-linked retinoschisis (XLRS) Phase 1/2 Phase 1/2 completion of enrollment announced April 10, 2018 with data due 4Q 2018.
AAV-based gene therapy X-linked Retinitis Pigmentosa (XLRP) Phase 1/2 Phase 1/2 dosing has commenced - noted April 18, 2018.
$29.18
-0.06  -0.21%
58.1 million
$1.7 billion
9.34
07/20/2018
Tap to view 5 drugs
Drug Indication Stage News
AR101 ARTEMIS Peanut Allergy Phase 3 Phase 3 enrollment has commenced - noted June 5, 2017. Data due 1Q 2019.
AR101 RAMSES Peanut Allergy Phase 3 Phase 3 initiation announced May 11, 2017. Data due 2H 2018.
AR101 PALISADE Peanut Allergy Phase 3 Phase 3 data released February 20, 2018 met primary endpoint. BLA filing due 2018.
AR 201 Egg Allergy Phase 2 Phase 2 trial to be initiated 1H 2019.
AR 301 Walnut Allergy Phase 2 Phase 2 trial to be initiated 2H 2019.
$7.14
-0.27  -3.64%
44.8 million
$319.8 million
10.91
07/20/2018
Tap to view 3 drugs
Drug Indication Stage News
C-Scape Complicated urinary tract infections (cUTI) due to multi-drug resistant (MDR) pathogens Phase 3 Phase 3 trial delayed due to decision to run a further Phase 1 trial first - noted May 4, 2018.
Plazomicin Complicated urinary tract infections (cUTI) Approved FDA approval for cUTI but CRL received for the treatment of bloodstream infection (BSI).
Plazomicin - CARE Serious bacterial infections due to carbapenem-resistant Enterobacteriaceae (CRE) Phase 3 Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.
$10.29
-0.22  -2.09%
56.9 million
$585.6 million
5.2
07/20/2018
Tap to view 4 drugs
Drug Indication Stage News
Vadadustat - TRILO2GY Three-times-weekly dosing regimen for vadadustat Phase 3 Phase 3 trial to be initiated in late 2018 or early 2019, with top-line results expected in early 2020.
Vadadustat - FO2RWARD Renal anemia Phase 2 Phase 2 trial data due 1H 2019.
Vadadustat - INNO2VATE Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD) Phase 3 Phase 3 data due 4Q 2019 or 1Q 2019.
Vadadustat - PRO2TECT Non-dialysis patients with anemia related to CKD (NDD-CKD) Phase 3 Phase 3 data due mid-2020.
$30.73
+0.48  +1.59%
85.6 million
$2.6 billion
32.02
07/20/2018
Tap to view 7 drugs
Drug Indication Stage News
AKCEA-ANGPTL3-LRx Rare hyperlipidemias Phase 2 Phase 2b initiated.
AKCEA-ANGPTL3-LRx Non-alcoholic fatty liver disease (NAFLD), Hypertriglyceridemia and Type 2 Diabetes Mellitus Phase 2 Phase 2 initiation announced December 14, 2017. Top-line data due 2019.
AKCEA-APOCIII-LRx Hyperlipoproteinemia and established cardiovascular disease Phase 2b Phase 2b trial initiation announced January 5, 2017. Top-line data due 2019.
AKCEA-APO(a)-LRx Hyperlipoproteinemia(a) and established cardiovascular disease Phase 2b Phase 2b completion of enrollment announced February 7, 2018. Data due 2H 2018.
Volanesorsen - APPROACH Familial chylomicronemia syndrome (FCS) PDUFA PDUFA August 30, 2018. Advisory Committee Meeting May 10, 2018 voted 10-8 in favor.
Volanesorsen Partial lipodystrophy rapidly Phase 3 Phase 3 initiated November 2015
Volanesorsen Familial partial lipodystrophy (FPL) Phase 3 Phase 3 initiated November 2015
$2.08
+0.02  +0.97%
15.3 million
$31.7 million
2.38
07/20/2018
Tap to view 4 drugs
Drug Indication Stage News
Coversin Paroxysmal nocturnal hemoglobinuria (PNH) Phase 2 Phase 2 interim data released April 24, 2017. Further update December 8, 2017 noted that primary endpoint was met. Phase 3 program to commence late 1Q 2018.
Coversin Atopic keratoconjunctivitis Phase 1 Phase 2 trial to be initiated 1H 2018.
Coversin Bullous Pemphigoid Phase 1 Phase 2 trial to be initiated 1H 2018.
Coversin Atypical hemolytic-uremic syndrome (aHUS) Phase 1 Phase 2 trial initiated late 2017.
$32.61
+0.06  +0.18%
11.9 million
$389.4 million
4
07/20/2018
Tap to view 1 drug
Drug Indication Stage News
A4250 Progressive familial intrahepatic cholestasis (PFIC) Phase 2 Phase 3 trial to be initiated spring 2018.
$7.90
-0.15  -1.86%
20.1 million
$158.9 million
4.32
07/20/2018
Tap to view 4 drugs
$1.09
+0.05  +4.81%
70 million
$76.3 million
5.79
07/20/2018
Tap to view 1 drug
Drug Indication Stage News
Iluvien Diabetic macular edema Approved CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
$45.04
-0.24  -0.53%
155 million
$7 billion
10.04
07/20/2018
Tap to view 10 drugs
Drug Indication Stage News
Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD) Schizophrenia Approved FDA approval announced July 2, 2018.
ALKS 3831 - ENLIGHTEN-Early Schizophrenia - young adults Phase 3 Phase 3 initiation announced June 8, 2017.
ALKS 3831 - ENLIGHTEN-2 Schizophrenia Phase 3 Phase 3 completion of enrollment announced April 26, 2018. Data due 4Q 2018.
BYDUREON Type 2 diabetes Approved CRL received March 15, 2010.
Aristada Schizophrenia Approved Approved October 5 2015. sNDA filed for 2-month option with approval announced June 6, 2017.
ALKS 8700 (BIIB098) Multiple sclerosis (MS) Phase 3 NDA filing due 4Q 2018.
ALKS 6428 Opioid dependence Phase 3 Phase 3 trial did not meet endpoint - February 2017. Second trial is ongoing.
ALKS 5461 Major depressive disorder PDUFA NDA filed but Refusal To File Letter announced April 2, 2018. However, company announced April 16, 2018 that the NDA has been accepted with a PDUFA date of January 31, 2019. Advisory Committee Meeting likely 4Q 2018.
ALKS 3831 - ENLIGHTEN-1 Schizophrenia Phase 3 Phase 3 preliminary data released June 30, 2017. Primary endpoint met - adverse events included weight gain.
ALKS 4230 Solid tumors Phase 1 Phase 2 trial to be initiated 2H 2018.
$35.05
+3.8  +12.16%
34.5 million
$1.2 billion
07/20/2018
Tap to view 4 drugs
Drug Indication Stage News
AK002 Severe Allergic Conjunctivitis Phase 1 Phase 1 data due 1Q 2019.
AK002 Indolent Systemic Mastocytosis Phase 1 Phase 1 data due 1Q 2019.
AK002 Chronic Urticaria Phase 2 Phase 2 data due 1Q 2019.
AK002 Eosinophilic Gastritis Phase 2 Phase 2 top-line data due mid-2019.
$11.39
+0.26  +2.34%
20.7 million
$235.7 million
2.06
07/20/2018
Tap to view 2 drugs
Drug Indication Stage News
ALLN-177 Enteric Hyperoxaluria Phase 3 Data from first Phase 3 trial due 2H 2019.
ALLN-177 Primary hyperoxaluria Phase 2 Phase 2 trial initiated March 2018 with interim data due 2H 2018 and top-line data due 2H 2019.
$105.93
-0.33  -0.31%
100.5 million
$10.6 billion
7.89
07/20/2018
Tap to view 13 drugs
Drug Indication Stage News
ALN-CC5 (cemdisiran) Atypical hemolytic-uremic syndrome (aHUS) Phase 1/2 Phase 2 trial initiation announced September 26, 2017 with initial data due 2018.
Fitusiran Hemophilia A and B Phase 2 Noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Announced December 15, 2017 that clinical hold has been released. Dosing to resume later December.
Givosiran Acute hepatic porphyrias Phase 3 Phase 3 trial initiation announced November 7, 2017 with interim analysis due September 2018.
Inclisiran - ORION-9 Hypercholesterolemia Phase 3 Phase 3 completion of enrollment announced February 20, 2018 enrollment to be completed 1H 2018. Data 3Q 2019.
ALN-HBV Chronic hepatitis B virus (HBV) Phase 1/2 Phase 1/2 trial initiated July 2016. Ongoing as of February 2017.
Lumasiran (ALN-GO1) Primary Hyperoxaluria Type 1 (PH1) Phase 3 Phase 1/2 positive data released November 11, 2017. Phase 3 trial to be initiated mid-2018 with data due 2019.
Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR PDUFA priority review PDUFA date under priority review August 11, 2018. ABUS entitled to low-mid single digit royalties.
Revusiran ENDEAVOUR ATTR in patients with familial amyloidotic cardiomyopathy (FAC) Phase 3 Phase 3 trial discontinued October 2016.
ALN-CC5 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 1/2 Phase 1/2 initial data presented at ASH 2016.
Fitusiran (ATLAS) Hemophilia Phase 3 Noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Announced December 15, 2017 that clinical hold has been released. Phase 3 first read-out expected 2H 2019
ALN-TTRsc02 ATTR amyloidosis Phase 1 Phase 3 trial to be initiated late 2018.
Inclisiran - ORION-10 Cardiovascular disease (ASCVD) Phase 3 Phase 3 enrollment target met - noted March 9, 2018. Data due 3Q 2019.
Inclisiran - ORION 11 Cardiovascular disease (ASCVD) Phase 3 Phase 3 target enrollment met - noted January 25, 2018. Data due 3Q 2019.
$8.13
-0.01  -0.12%
13.8 million
$112.6 million
2.28
07/20/2018
Tap to view 1 drug
Drug Indication Stage News
N91115 Cystic Fibrosis - one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein Phase 2 Phase 2 data released February 24, 2017 - primary endpoint not met.
$4.28
+0.06  +1.42%
14.7 million
$63.1 million
2.53
07/20/2018
Tap to view 3 drugs
Drug Indication Stage News
ALRN-6924 Peripheral T-cell lymphoma (PTCL) Phase 2a Phase 2a interim data due 2H 2018.
ALRN-6924 Solid tumors - cancer Phase 1/2 Phase 1 initial data presented at ASCO 2017. Completion of enrollment January 2017.
ALRN-6924 Acute myeloid leukemia (AML); Myelodysplastic syndrome (MDS) Phase 1b Phase 1/1b open label data due 2H 2018.
$0.40
+0.04  +11.08%
38.3 million
$15.3 million
1.09
07/20/2018
Tap to view 3 drugs
Drug Indication Stage News
HepTCell Hepatitis B Phase 1 Phase 1 data due early 4Q 2018.
NasoVAX Flu vaccine Phase 2 Phase 2 additional data due 3Q 2018.
NASOSHIELD Anthrax Phase 1 Phase 1 data due early 3Q 2018.
$135.16
+0.07  +0.05%
222.5 million
$30.1 billion
3.25
07/20/2018
Tap to view 6 drugs
Drug Indication Stage News
Eculizumab Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD) Phase 3 Phase 3 enrollment complete with data due by the end of 2018.
ALXN1210 atypical Hemolytic Uremic Syndrome (aHUS) Phase 3 Phase 3 enrollment to be completed 2Q 2018 with data due 4Q 2018.
ALXN1101 Molybdenum cofactor deficiency (MoCD) Type A Phase 2/3 Phase 2/3 enrolling.
ALXN1210 Paroxysmal nocturnal hemoglobinuria (PNH) BLA Filing BLA filing announced June 19, 2018.
SBC-103 MPS IIIB Phase 1/2 Phase 1/2 ongoing. No additional studies planned.
Eculizumab Refractory generalized myasthenia gravis (gMG) Approved Approval announced October 23, 2017.
$21.85
-0.3  -1.35%
34.3 million
$750 million
11.85
07/20/2018
Tap to view 5 drugs
Drug Indication Stage News
Digoxin immune fab (DIF) Severe preeclampsia in pregnant women Phase 2/3 Phase 2/3 commencement of enrollment announced June 1, 2017.
Rekynda Hypoactive sexual desire disorder (HSDD) Phase 3 NDA filing due early 2018.
Rekynda (Bremelanotide) Female sexual dysfunction (FSD) PDUFA PDUFA date March 23, 2019.
Feraheme Adults with iron deficiency anemia (IDA) Approved Approval for sNDA filing announced February 5, 2018.
Makena - auto injector Reduce the risk of preterm birth in women with a singleton pregnancy Approved Approval announced February 14, 2018.
AMGN Amgen Inc.
$190.49
-1.27  -0.66%
661.7 million
$126 billion
3
07/20/2018
Tap to view 18 drugs
Drug Indication Stage News
Tezepelumab Asthma Phase 3 Phase 2b data released September 7, 2017 - primary endpoint met. Phase 3 trial enrolling.
Prolia (denosumab) Glucocorticoid-induced osteoporosis (GIOP) Approved Approval announced May 21, 2018.
KYPROLIS (ASPIRE) Relapsed Multiple Myeloma Approved sNDA approval announced June 11, 2018.
Vectibix (Panitumumab) Wild-Type RAS Metastatic Colorectal Cancer Approved sBLA approval announced June 29, 2017.
MVASITM (bevacizumab-awwb) Biosimilar candidate to Avastin (bevacizumab) PDUFA Approved September 14, 2017.
Corlanor Chronic Heart Failure Approved Approved April 15, 2015.
Erenumab Migraine Approved Approval announced May 17, 2018.
CNP 520 Alzheimer’s Disease Phase 2/3 Phase 2/3 ongoing. Expected completion 2024.
Repatha Cardiovascular disease Approved Approval announced December 1, 2017.
XGEVA Multiple Myeloma Approved sBLA approval announced January 5, 2017.
KYPROLIS (ARROW) Multiple Myeloma Phase 3 Phase 3 trial data presented at ASCO June 1, 2018. 3.6 month improvement in PFS.
KYPROLIS (ENDEAVOR) Relapsed Multiple Myeloma Approved sNDA approved January 17, 2018.
BLINCYTO Ph+ R/R ALL Approved PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.
ABP 798 RITUXAN biosimilar - non-Hodgkin lymphoma Phase 3 Phase 3 enrolling.
ABP 980 Herceptin biosimilar BLA Filing BLA filing announced July 31, 2017.
ABP 710 REMICADE biosimilar - rheumatoid arthritis Phase 3 Phase 3 data likely due 2H 2018.
Parsabiv Secondary hyperparathyroidism (SHPT) Approved Approved February 7, 2017.
EVENITY (Romosozumab) Osteoporosis BLA Filing CRL issued July 16, 2017. BLA resubmission announced July 13, 2018.
$2.63
+0.27  +11.44%
86.3 million
$227 million
14.76
07/20/2018
Tap to view 2 drugs
$16.90
+0.26  +1.56%
46.6 million
$787.8 million
6.13
07/20/2018
Tap to view 3 drugs
Drug Indication Stage News
Albuterol DPI Asthma Phase 2b
Naloxone Intranasal Opioid overdose CRL CRL announced February 21, 2017.
Primatene Mist (epinephrine inhalation aerosol) Asthma CRL CRL issued December 27, 2016.
$2.80
+0.03  +1.08%
293.6 million
$822 million
2.64
07/20/2018
Tap to view 1 drug
Drug Indication Stage News
Vascepa REDUCE-IT outcomes trial High Triglycerides With Mixed Dyslipidemia Phase 3 Data due before the end of 3Q 2018.
$18.52
+0.03  +0.16%
73.9 million
$1.4 billion
5.2
07/20/2018
Tap to view 1 drug
Drug Indication Stage News
IPX203 Parkinson's disease Phase 3 Phase 3 initiation announced May 7, 2018.
$76.51
+2.75  +3.73%
23.5 million
$1.8 billion
5.74
07/20/2018
Tap to view 4 drugs
Drug Indication Stage News
ANB020 Moderate-to-severe adult atopic dermatitis Phase 2b Phase 2b data due 2019.
ANB020 Severe adult eosinophilic asthma Phase 2a Phase 2a data due 3Q 2018.
ANB020 Severe adult peanut allergy Phase 2a Phase 2a data released March 26, 2018 - 6/13 showed improved tolerance.
ANB019 Palmo-plantar pustular psoriasis Phase 2 Phase 2 trial to be initiated 2019.
$34.23
+0.11  +0.32%
14.3 million
$489.8 million
6.14
07/20/2018
Tap to view 3 drugs
Drug Indication Stage News
Cingal Osteoarthritis Phase 3 Phase 3 trial did not meet primary endpoint - June 19, 2018.
Monovisc Osteoarthritis Approved Approved Feb 2014
HYALOFAST Cartilage defects of the knee Phase 3 Phase 3 enrollment to be completed by the end of 2018.
$0.08
-0.01  -5.88%
26.2 million
$2.1 million
2.04
07/20/2018
Tap to view 4 drugs
Drug Indication Stage News
Sollpura - RESULT Exocrine pancreatic insufficiency Phase 3 Phase 3 data released March 12, 2018 did not meet primary endpoint.
Blisibimod IgA nephropathy Phase 2 Phase 2 primary endpoint not met following interim analysis. Trial to continue. Top-line data released August 28, 2017.
Sollpura (liprotamase) Cystic fibrosis who suffer from exocrine pancreatic insufficiency Phase 3 Top-line data released December 27, 2016 - missed primary endpoint.
Blisibimod Lupus Phase 3 Phase 3 trial did not meet endpoints - November 10, 2016.
$1.12
+0.03  +2.75%
16.5 million
$18.4 million
7.27
07/20/2018
Tap to view 1 drug
Drug Indication Stage News
AB-SA01 Life-threatening infections Phase 2 Phase 2 trial planned for 4Q 2018.
$18.28
-0.31  -1.67%
55.9 million
$1 billion
4.75
07/20/2018
Tap to view 5 drugs
Drug Indication Stage News
APL-2 subcutaneous Complement-dependent Nephropathies (CDN) Phase 2 Phase 2 monotherapy data due 2H 2018.
APL-2 subcutaneous Auto-immune Hemolytic Anemia (AIHA) Phase 2 Phase 2 monotherapy data due 1H 2018 (overdue - shifted to 3Q in the calendar).
APL-2 subcutaneous and eculizumab (Soliris) Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 1b Phase 1b eculizumab add-on and monotherapy expansion updates released June 2018.
APL-2 IV - FILLY Geographic atrophy (GA) Phase 3 Phase 3 trial to commence 2H 2018. Phase 2 18 month safety & efficacy data released February 22, 2018.
APL-2 subcutaneous Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 3 Phase 3 trial initiation announced June 26, 2018.
$0.40
-0.01  -2.91%
23.4 million
$9.4 million
0.91
07/20/2018
Tap to view 1 drug
$3.13
-0.17  -5.15%
33.4 million
$104.6 million
0.36
07/20/2018
Tap to view 1 drug
Drug Indication Stage News
APTO-253 Acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) Phase 1b Phase 1b clinical hold released June 29, 2018.
$20.21
-0.14  -0.69%
32.5 million
$657.6 million
0.87
07/20/2018
Tap to view 3 drugs
Drug Indication Stage News
NYX-458 Post-traumatic stress disorder (PTSD) Phase 1/2 Phase 1 trial to be initiated 1H 2018.
NYX-2925 Fibromyalgia Phase 2 Phase 2 data due 1H 2019.
NYX-2925 Neuropathic Pain Associated with Diabetic Peripheral Neuropathy Phase 2 Phase 2 data due 1H 2019.
$3.01
-0.16  -5.05%
23.5 million
$70.8 million
0.64
07/20/2018
Tap to view 4 drugs
Drug Indication Stage News
Rosiptor (AQX-1125) Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Phase 2 Phase 2 trial initiation announced June 11, 2018.
AQX-1125 LEADERSHIP Bladder pain syndrome/interstitial cystitis (BPS/IC) Phase 3 Phase 3 data released June 27, 2018. Primary endpoint not met.
AQX-1125 KINSHIP Atopic dermatitis (AD) Phase 2 Phase 2 failed to demonstrate efficacy November 2015
AQX-1125 FLAGSHIP Chronic obstructive pulmonary disease (COPD) Phase 2 Phase 2 trail failed - July 2015
$1.46
-0.01  -0.68%
15.2 million
$22.2 million
3.53
07/20/2018
Tap to view 2 drugs
$4.40
  +0.00%
60.1 million
$264.5 million
0.93
07/20/2018
Tap to view 4 drugs
Drug Indication Stage News
Tenapanor (T3MPO-2) Constipation-predominant irritable bowel syndrome (IBS-C) Phase 3 Phase 3 data released October 11, 2017. Primary endpoint met but with relatively high rates of diarrhea. NDA filing due 2H 2018.
RDX7675 Hyperkalemia Phase 2 Onset of action trial data released November 21, 2017 - noted significantly reduced serum potassium in patients. Development to be discontinued.
Tenapanor Hyperphosphatemia in end-stage renal disease (ESRD) patients Phase 3 Phase 3 released February 15, 2017 - primary endpoint met. Data from second Phase 3 trial due 2019.
Tenapanor (T3MPO-1) Constipation-predominant irritable bowel syndrome (IBS-C) Phase 3 Phase 3 data released May 12, 2017. Primary endpoint met - however, competitive concerns raised.
ARGX argenx SE
$96.21
+3.17  +3.41%
32.4 million
$3.1 billion
0.95
07/20/2018
Tap to view 5 drugs
$0.31
+0.06  +25.46%
67 million
$21.1 million
3.69
07/20/2018
Tap to view 2 drugs
Drug Indication Stage News
VIMOVO Gastric ulcers Approved Approved April 30, 2010.
YOSPRALA (PA32540/PA8140) Secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers Approved Approval announced September 15, 2016.
$0.00
  +0.00%
30.4 million
$
0.82
07/20/2018
Tap to view 4 drugs
Drug Indication Stage News
AM0010 (PEG-IL-10) and Nivolumab - Cypress 2 Non-small cell lung cancer (NSCLC) Phase 2b Phase 2b initiation announced March 29, 2018 with preliminary data due over the course of 2018.
AM0010 (PEG-IL-10) and Pembrolizumab - Cypress 1 Non-small cell lung cancer (NSCLC) Phase 2b Phase 2b initiation announced March 29, 2018 with preliminary data due end of 2018.
AM0010 (PEG-IL-10) Solid tumors Phase 1b Phase 1/1b trial ongoing. Data presented at ASCO June 2018.
AM0010 (PEG-IL-10) pancreatic ductal adenocarcinoma (PDAC) Phase 3 Phase 3 interim analysis March 26, 2018. Trial to continue. Second analysis and final data due 2020.
$43.82
-0.69  -1.55%
49.2 million
$2.2 billion
4.96
07/20/2018
Tap to view 8 drugs
Drug Indication Stage News
Etrasimod Primary biliary cholangitis (PBC) Phase 2 Phase 2 initiated 2017.
Etrasimod Pyoderma gangrenosum (PG) Phase 2 Phase 2 trial initiated March 2017.
Etrasimod Dermatological extraintestinal manifestations (EIM) in patients with inflammatory bowel disease (IBD) Phase 2 Phase 2 trial initiated March 2017.
Lorcaserin Obesity Approved Approved June 27, 2012.
Olorinab (APD371) Pain associated with Crohn's disease Phase 2 Phase 2 data due 3Q 2018.
Lorcaserin Smoking cessation Phase 2 Phase 2 initiated March 2014. Data released Nov 2014
Etrasimod Ulcerative colitis Phase 2 Phase 2 data released March 19, 2018 - primary and secondary endpoints met.
Ralinepag Pulmonary Arterial Hypertension Phase 2 Phase 2 data released July 10, 2017. Primary endpoint met. Secondary missed. Phase 3 trial to be initiated 2H 2018.
$5.38
+0.17  +3.26%
99.8 million
$536.8 million
3.05
07/20/2018
Tap to view 6 drugs
Drug Indication Stage News
ARQ 092 Overgrowth Diseases Phase 1/2 Phase 1/2 trial has commenced enrollment - May 4, 2017.
Derazantinib (ARQ 087) intrahepatic cholangiocarcinoma (iCCA) Phase 3 Phase 1/2 interim data due 2019.
Tivantinib (ARQ 197) METIV-HCC trial Previously treated Inoperable Hepatocellular Carcinoma cancer Phase 3 Phase 3 top-line data released February 17, 2017 - primary endpoint not met.
Miransertib - ARQ 092 Solid tumors Phase 1b Phase 1b data due 2019.
ARQ 531 B-cell malignancies Phase 1a Phase 1a data due 2H 2018.
ARQ 751 Solid tumors Phase 1 Phase 1a data due 2H 2018.
$16.98
-0.1  -0.59%
210.6 million
$3.6 billion
4
07/20/2018
Tap to view 10 drugs
Drug Indication Stage News
ARRY-382 and Keytruda Non-small cell lung cancer Phase 1/2 Phase 1/2 initial efficacy data presented in poster November 10, 2017 at SITC.
Selumetinib - ASTRA Thyroid cancer Phase 3 Phase 3 data 2H 2018.
Selumetinib - SELECT-1 Differentiated thyroid cancer Phase 3 Phase 3 trial did not meet its primary endpoint - August 2016
Binimetinib - COLUMBUS BRAF mutant melanoma cancer Approved Approval announced June 27, 2018.
ARRY 797 LMNA A/C-related dilated cardiomyopathy (DCM) Phase 3 Phase 3 trial initiated 1Q 2018.
Binimetinib (NEMO) NRAS melanoma - cancer Phase 3 PDUFA date originally set for June 30, 2017. Announed withdrawl of NDA filing - March 20, 2017.
Encorafenib and cetuximab - BEACON CRC BRAF-Mutant Colorectal Cancer Phase 3 Updated data June 23, 2018 noted one-year overall survival rate for this cohort was 62%. Median OS not yet reached. ORR 48%.
Binimetinib - MILO Recurrent low-grade serous ovarian cancer (LGSOC) Phase 3 Phase 3 trial discontinued April 2016
Binimetinib and nivolumab Colorectal cancer Phase 1 Phase 1 planned.
Binimetinib and avelumab/talazoparib Non-small cell lung cancer (NSCLC) and pancreatic cancer Phase 1b Phase 1b trial to be initiated 3Q 2018.
$16.03
-0.28  -1.72%
87.6 million
$1.4 billion
4.67
07/20/2018
Tap to view 5 drugs
$7.83
-0.04  -0.51%
33.5 million
$262.5 million
0.05
07/20/2018
Tap to view 4 drugs
Drug Indication Stage News
Varlitinib Biliary tract cancer Phase 2/3 China data due late 2018. Global data due 2019.
Varlitinib Gastric cancer Phase 2/3 Phase 2 data due 2H 2018.
Varlitinib Gastric cancer Phase 1/2 Phase 1/2 interim data due late 2018.
ASLAN002 Acute Myeloid Leukemia (AML) Phase 2 Phase 2 interim data due 2H 2018.
$41.84
+0.66  +1.60%
25.2 million
$1.1 billion
3.86
07/20/2018
Tap to view 2 drugs
$69.18
-1.67  -2.36%
41.8 million
$2.9 billion
1.77
07/20/2018
Tap to view 3 drugs
Drug Indication Stage News
TransCon Growth hormone deficiency in children Phase 3 Phase 3 completion of enrollment announced January 3, 2018. Data due 1Q 2019.
TransCon Hypoparathyroidism Phase 1 Phase 1 poster presented at European Congress of Endocrinology (ECE) May 2018.
TransCon CNP Achondroplasia Phase 1 Phase 1 initiation of dosing announced May 8, 2018 with data due 4Q 2018.
$3.03
-0.14  -4.42%
14.3 million
$43.3 million
1.98
07/20/2018
Tap to view 1 drug
Drug Indication Stage News
ASN100 Staphylococcus aureus Phase 2 Phase 2 trial to be discontinued due to futility - June 28, 2018.
$1.80
+0.05  +2.86%
55 million
$99 million
12.77
07/20/2018
Tap to view 3 drugs
Drug Indication Stage News
AST-VAC2 Non-small cell lung cancer (NSCLC) Phase 1/2 Safety review recommended July 11, 2018 that trial should continue.
AST-OPC1 SCiSTAR Cervical spinal cord injury Phase 1/2 Phase 1/2 6-month data from cohort 5 released July 17, 2018. 12-mth data on cohorts 3 and 4 due 3Q 2018 with 12-mth data from all cohorts due 1Q 2019.
AST-VAC1 Acute myeloid leukemia (AML) Phase 2b Phase 2b planned for 2018.
$2.07
  +0.00%
138 million
$285.6 million
7.15
07/20/2018
Tap to view 4 drugs
Drug Indication Stage News
Multistem - TREASURE (Japan) Ischemic stroke Phase 2/3 Phase 2/3 enrollment commenced November 2017 (Japan).
Multistem Ischemic stroke